INHIBITION OF GIIA PHOSPHOLIPASE A₂ BY 2-Oxoamides Based on α-Amino Acids: Exploring the Role of the α-Amino Acid

S. Vasilakaki, N. Stavrinoudakis, E. Barbayianni, T. Mavromoustakos, G. Kokotos

Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Athens Panepistimiopolis, Athens 15771, Greece

gkokotos@chem.uoa.gr

INTRODUCTION

Group IIA secreted phospholipase A_2 (GIIA sPLA₂) is a member of the mammalian sPLA₂ enzyme superfamily which are characterised by their ability to catalyse the hydrolysis of the sn-2 ester bond of glycerophospholipids releasing free fatty acids.¹ The crystal structure of the enzyme reveals a highly conserved Ca²⁺ binding loop and a catalytic dyad consisting of His47/Asp91. The mechanism of the substrate hydrolysis includes the activation of a water molecule by His47 and consequently an attack to the sn-2 ester carbonyl carbon of the substrate. GIIA sPLA₂ is associated with various inflammatory conditions and therefore is considered to be an anti- inflammatory drug target.² Kokotos et al have developed a novel class of inhibitors (**1a**, **1b**) for cytosolic phospholipase A₂ (GIVA cPLA₂).³ Most recently, they found that the long chain 2-oxoamide **2** based on the amino acid (S)-leucine displayed inhibition of human and mouse GIIA sPLA₂ (IC₅₀ 300 nM and 180 nM, respectively).⁴ Here, we present a series of docking experiments of long chain 2-oxoamide derivatives based on the proteinogenic aamino acids. The structures were designed using the same motif: a long chain 2-oxoamide (same for all structures) and an amino acid unit.

RESULTS AND DISCUSSION

Evaluating the docking results, among the structures with Score Fitness higher than 97kJ/mol, the stuctures based on glutamic acid ethylester **3**, glutamic acid **4**, histidine **5** were of the outmost interest. Only a slight change in the position of these ligands in the active site was observed, comparing to the reference ligand 2 placement. More specifically, the conformation they take up is similar to the ligand **2** (**Figure 1**) and the key interactions with the active site are preserved (**Figure 2**). Moreover, in the case of ligand **4**, it is the carbonyl oxygen of the side chain of the a-amino acid that interacts with the Ca²⁺ and not the oxygen of the carbonyl group as it happens in ligand **2**. This new interaction led us to design ligand **3** which gave improved results. Synthesis of the molecules **3-5**, which show the higher docking scoring, is in progress in an attempt to test the parallelism between docking scoring and bioactivity.



Performing Docking Experiments

Simulated docking was used for the study of new structures with potential inhibitory activity towards GIIA sPLA₂. Based on previous work,⁴ Sybyl 8.0 by TRIPOS was used for the design, the energy minimisation and the simulated annealing of the structures while Gold 5.0.1 by Gold company was chosen for the



docking. The ligands were sketched taking in to account the correct ionization and tautomeric states of the molecules and the Powell algorithm was used for the energy minimisation.

For the docking process the crystal structure of GIIA sPLA₂ was retrieved from the Brookhaven Protein Databank (PDB code: 1DB4). From this structure, water molecules within a distance of 5Å from the active site were set to 'Toggle' and 'Spin' state and all water molecules in a greater distance were deleted. Setting up the active site, all the protein residues within 6.0Å distance of the bound ligand were marked with their charge in physiological pH in order to form sensible interactions with the substrate. The calcium ion was treated in order to have the correct geometry and formal charge.

Substrate **2** was docked first in order to reassure that all the parameters were set up correctly and to ensure the production of reliable docking results. **Table 1** summarizes all the docking results of the 2-oxoamide derivatives of all the proteinogenic a-amino acids.

Compound	GoldScoreFitness (kJ/mol)	Compound	GoldScoreFitness (kJ/mol)	a- amino acid $ \begin{array}{c} $	C
$ \begin{array}{c} 0 \\ H \\ 0 \\ 13 \\ 0 \end{array} $	Et 7		Ъ	o ĸ Aspartic acid	
HO HO	100.74	O N N	97.15	Methionine Glutamine	
Glutam & acid ethylester		5 Histidine		Proline	

Figure 1: Conformation of the ligands **2-5** in the active site of GIIA sPLA₂.

$ \begin{array}{c} $	97.43	O 13 O K O K O K O K O K O K O K O K O K O K O K O K O K O K O K O K O C N O C N O C N O C N O C C C O C C O C C C O C C C O C C C C C C C C C C C C C	o H H H H H H H H H H H H H H H H H H H	83.85

Table 1: Docking Score Fitness of all the 2-oxoamide derivatives of α -amino acids.



Cysteine	88.86
Threonine	86.39
Tryptophan	85.05
Asparagine	85.79
Serine	87.14
Lysine	84.76
Phenilalanine	80.84
Valine	78.22
Glycine	77.12
Alanine	79.80
Tyrosine	79.18
Isoleucine	79.10

oldScoreFitness

(kJ/mol)

97.56

97.40

90.63

89.76

89.37

Figure 2: Key interactions between the ligands and the active site. Interestingly, the Ca²⁺ ion interacts with 2 oxygen atoms of the ligand (important for the inhibition) in all structures. The H-bonds interactions between the amino and carbonyl groups of the structures and the enzyme's residues are also important for the binding.

References

Dennis, E. A.; Cao, J.; Hsu, Y. H.; Magrioti, V.; Kokotos, G. *Chem. Rev.* 2011, accepted.
 Mouchlis, V.D.; Barbayianni, E.; Mavromoustakos, T.M.; Kokotos, G. *Curr. Med. Chem.*

2011, 18, 2566.

- Kokotos, G.; Six, D. A.; Loukas, V.; Smith, T.; Constantinou-Kokotou, V.; Hadjipavlou-Litina, D.; Kotsovolou, S.; Chiou, A.; Beltzner C. C.; Dennis, E.A. J. Med. Chem. 2004, 47, 3615.
- Mouchlis, V. D.; Magrioti, V.; Barbayianni, E.; Cermak, N.; Oslund, R. C.; Mavromoustakos, T. M.; Gelb, M. H.; Kokotos, G. *Bioorg. Med. Chem.* 2011, 19, 735.